Oculis Holding AG to participate in multiple investor conferences in September, discussing updates and innovations in ophthalmic treatments.
Quiver AI Summary
Oculis Holding AG, a biopharmaceutical company based in Switzerland that develops innovative treatments for ophthalmic and neuro-ophthalmic diseases, announced its participation in several investor conferences scheduled for September 2025. Key executives, including CEO Riad Sherif, will present updates and engage in discussions at events such as the Wells Fargo Healthcare Conference in Boston and the Baird Global Healthcare Conference in New York. The company will also host a fireside chat and will be available for one-on-one meetings with investors. Oculis is focused on addressing significant unmet medical needs with its late-stage clinical pipeline, which includes products like OCS-01 for diabetic macular edema and OCS-05 for acute optic neuritis. Further details can be found on the company’s website.
Potential Positives
- Management's participation in multiple high-profile investor conferences demonstrates Oculis' proactive approach to engaging with the investment community and could enhance visibility and investor interest.
- The upcoming fireside chat and company updates led by the CEO provide a platform for Oculis to communicate its strategic vision and advancements in its clinical pipeline.
- The inclusion of detailed information about the company’s innovative product candidates highlights Oculis’ commitment to addressing significant unmet medical needs in ophthalmic and neuro-ophthalmic diseases, potentially attracting interest from investors and partners.
Potential Negatives
- While the press release outlines multiple upcoming investor conferences, the lack of specific details regarding the company's current financial performance or projections may raise concerns among potential investors about transparency.
- The announcement of participation in investor conferences, while positive in engagement, may also indicate that the company is seeking additional funding or investor interest, which could suggest cash flow or operational challenges.
- There is no mention of clinical trial results or progress updates for the product candidates, which may lead to speculation about delayed timelines or efficacy concerns in a competitive biopharmaceutical market.
FAQ
What upcoming investor conferences will Oculis attend in September?
Oculis will participate in the Wells Fargo Healthcare Conference, H.C. Wainwright Global Investment Conference, and more in September 2025.
Who are the key executives representing Oculis at these conferences?
Riad Sherif, M.D., CEO, and Sylvia Cheung, CFO, will represent Oculis at various investor conferences.
Where can I find webcast links for Oculis' presentations?
Webcast links will be posted on the Oculis website under the Events & Presentation page in the Investors & Media section.
What is Oculis focused on developing?
Oculis develops innovative solutions for ophthalmic and neuro-ophthalmic diseases, addressing significant unmet medical needs.
How can investors schedule one-on-one meetings with Oculis during the conferences?
Interested investors should contact their representatives at the sponsoring institutions to request one-on-one meetings with Oculis.
Disclaimer: This is an AI-generated summary of a press release distributed by GlobeNewswire. The model used to summarize this release may make mistakes. See the full release here.
$OCS Hedge Fund Activity
We have seen 13 institutional investors add shares of $OCS stock to their portfolio, and 8 decrease their positions in their most recent quarter.
Here are some of the largest recent moves:
- WOODLINE PARTNERS LP added 50,568 shares (+inf%) to their portfolio in Q2 2025, for an estimated $981,524
- CITADEL ADVISORS LLC removed 22,911 shares (-100.0%) from their portfolio in Q1 2025, for an estimated $435,996
- MARSHALL WACE, LLP added 20,253 shares (+inf%) to their portfolio in Q2 2025, for an estimated $393,110
- POLEN CAPITAL MANAGEMENT LLC added 19,472 shares (+inf%) to their portfolio in Q2 2025, for an estimated $377,951
- BOSUN ASSET MANAGEMENT, LLC added 19,472 shares (+inf%) to their portfolio in Q2 2025, for an estimated $377,951
- ACUTA CAPITAL PARTNERS, LLC removed 18,282 shares (-14.6%) from their portfolio in Q2 2025, for an estimated $354,853
- UBS GROUP AG added 13,550 shares (+12.0%) to their portfolio in Q2 2025, for an estimated $263,005
To track hedge funds' stock portfolios, check out Quiver Quantitative's institutional holdings dashboard.
$OCS Analyst Ratings
Wall Street analysts have issued reports on $OCS in the last several months. We have seen 3 firms issue buy ratings on the stock, and 0 firms issue sell ratings.
Here are some recent analyst ratings:
- HC Wainwright & Co. issued a "Buy" rating on 08/22/2025
- Chardan Capital issued a "Buy" rating on 05/09/2025
- Baird issued a "Outperform" rating on 03/13/2025
To track analyst ratings and price targets for $OCS, check out Quiver Quantitative's $OCS forecast page.
$OCS Price Targets
Multiple analysts have issued price targets for $OCS recently. We have seen 4 analysts offer price targets for $OCS in the last 6 months, with a median target of $34.5.
Here are some recent targets:
- Serge Belanger from Needham set a target price of $36.0 on 08/27/2025
- Yi Chen from HC Wainwright & Co. set a target price of $33.0 on 08/22/2025
- Daniil Gataulin from Chardan Capital set a target price of $33.0 on 05/09/2025
- Colleen Kusy from Baird set a target price of $41.0 on 03/13/2025
Full Release
ZUG, Switzerland, Aug. 28, 2025 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS / XICE: OCS) (“Oculis”), a global biopharmaceutical company focused on developing innovative solutions for ophthalmic and neuro-ophthalmic diseases with significant unmet medical needs, announced today that Oculis’ management will participate in upcoming investor conferences in September.
Wells Fargo Healthcare Conference
September 3-5; Boston, U.S.
Riad Sherif, M.D., Chief Executive Officer, and Sylvia Cheung, Chief Financial Officer, will attend.
H.C. Wainwright 27th Annual Global Investment Conference
September 8-10; New York, U.S.
Fireside chat with Riad Sherif, M.D., Chief Executive Officer, scheduled for September 8
th
at 2:30 pm ET.
Webcast Link:
Register here
Baird Global Healthcare Conference
September 9-10; New York, U.S.
Company update with Riad Sherif, M.D., Chief Executive Officer, scheduled for September 9
th
at 3:45 pm ET.
Webcast Link:
Register here
Pareto Securities 16th Annual Healthcare Conference
September 16; Stockholm, Sweden
Company update with Páll Ragnar Jóhannesson, Chief Business Officer, scheduled for September 16
th
at 9:15 am CET.
Leerink Partners Biopharma Summit
September 17-19; Healdsburg, U.S.
Riad Sherif, M.D., Chief Executive Officer, will attend.
The Company will be available for one-on-one meetings during the conferences. Interested investors should contact their respective representative at the sponsoring institutions to request meetings.
Webcast links, when available, will be posted to the Oculis website on the Events & Presentation page under the Investors & Media section.
-END-
About Oculis
Oculis is a global biopharmaceutical company (Nasdaq: OCS; XICE: OCS) focused on innovations addressing ophthalmic and neuro-ophthalmic conditions with significant unmet medical needs. Oculis’ highly differentiated late-stage clinical pipeline includes three core product candidates: OCS-01, an eye drop in pivotal registration studies, aiming to become the first non-invasive topical treatment for diabetic macular edema; Privosegtor (OCS-05), a neuroprotective candidate in Phase 2 for acute optic neuritis, with potentially broad clinical applications in various neuro-ophthalmic and neurological diseases; and Licaminlimab (OCS-02), a novel topical anti-TNFα in Phase 2, being developed with a genotype-based approach to drive personalized medicine in dry eye disease (DED). Headquartered in Switzerland with operations in the U.S. and Iceland, Oculis is led by an experienced management team with a successful track record and supported by leading international healthcare investors.
For more information, please visit: www.oculis.com
Oculis Contacts
Ms. Sylvia Cheung, CFO
[email protected]
Investor Relations
LifeSci Advisors
Corey Davis, Ph.D.
[email protected]
Media Relations
ICR Healthcare
Amber Fennell / David Daley / Sean Leous
[email protected]
